JPRN-UMIN000003793已完成2 期
Phase II study of R-CODOX-M/R-IVAC therapy for the patients with newly diagnosed primary mediastinal large B-cell lymphoma - PMBL-R-CODOX-M/R-IVAC-P2
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 59years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Uncontrollable hypertension. 2) History of myocardial infarction or angina or cardiomyopathy. 3) HBs antigen positive, HCV antibody positive or HIV antibody positive. 4) Accompanying interstitial pneumonitis, pulmonary fibrosis, or severe emphysema (all apparently diagnosed by chest X-ray). 5) Severe infections. 6) Liver cirrhosis, either biopsy proven or clinically diagnosed. 7) Active double cancer: overlapping cancer or asynchronous cancer within 5 years. Carcinoma in situ, intramucosal cancers, and other equivalent lesions are not included for the active double cancer. 8) Women during pregnancy, lactation period or of childbearing potentials not using a reliable contraceptive method. 9) Use of major tranquilizer, antidepressant or antimanic, or severe psychosis. 10) History of allogeneic or autologous hematopoietic stem cell transplantation.
研究者
相似试验
进行中（未招募）
1 期
A Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt's Lymphoma (BL) of International Prognostic Index (IPI) High or High-Intermediate Risk - R-CODOX-M/IVACEUCTR2005-003479-19-GBniversity College London150
进行中（未招募）
1 期
Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphomaEUCTR2013-004394-27-BEHOVON Foundation260
招募中
3 期
Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphomaNL-OMON53047HOVO90
进行中（未招募）
1 期
A clinical study comparing two different chemotherapy options for patients with newly diagnosed Burkitt lymphomaHigh-risk Burkitt lymphomaMedDRA version: 20.0Level: LLTClassification code 10006605Term: Burkitt's tumor or lymphomaSystem Organ Class: 100000004864EUCTR2013-004394-27-GBHOVON Foundation260
进行中（未招募）
1 期
Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphomaHigh risk Burkitt LymphomaMedDRA version: 20.0 Level: LLT Classification code 10006605 Term: Burkitt's tumor or lymphoma System Organ Class: 100000004864EUCTR2013-004394-27-NLHOVON Foundation260